Oak Hill Bio to Participate in Citi 17th Annual BioPharma Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oak Hill Bio (“Oak Hill”), a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases, today announced that members of its senior leadership team will participate in one-on-one meetings with investors at the upcoming Citi 17^th Annual BioPharma Conference taking place on September 7-8, 2022, in Boston, MA.

For additional information or to schedule a one-on-one meeting with members of the Oak Hill management team, please contact your Citi representative.

About Oak Hill Bio

Oak Hill Bio is a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The company, which has operations in the United States and United Kingdom, was launched to develop a pipeline of six promising clinical-stage and preclinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited (“Takeda”). For more information on Oak Hill Bio, visit the company’s website at www.oakhillbio.com.

Contacts

Investors
Josh Distler

Oak Hill Bio

[email protected]

Anne Marie Fields

Stern Investor Relations

[email protected]
212-362-1200

Media
Chris Railey

Ten Bridge Communications

[email protected]
617-834-0936